The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training

Inclusion Criteria:

• Participation in the SÄPT therapist training (medical doctors and psychologists)

• Age 27 years or older

• Sufficient understanding of the German language

• Understanding of procedures and risks associated with the study

• Willing to adhere to the protocol and signing of the consent form

• Willing not to operate heavy machinery (including driving cars) within 24 hoursafter substance administration

• Woman of childbearing potential are required to use effective, establishedcontraception, such as oral, injected or implanted hormonal methods ofcontraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier methods of contraception: condom or occlusive cap (diaphragm orcervical/vault caps) with spermicidal foam/gel/film/cream/suppository at least onemonth before and after each study substance intervention, and are willing to take aurine pregnancy test at the medical screening and before every study substanceintervention.

• Men are required to use contraceptive methods in the month after each studysubstance intervention and are required to inform their partner(s) about their studyparticipation.

Exclusion Criteria:

• Previous significant adverse response to a hallucinogenic drug

• Significant medical condition rendering volunteers unsuitable for participation (such as impaired kidney or liver function, or heart disease incl. uncontrolledhypertension or hypotension)

• Strong underweight (<45kg)

• Current major psychiatric disorder (including personality disorder, includingsuicidality) and / or previous psychotic or bipolar disorder.

• Psychotic disorder or bipolar disorder in first-degree relatives

• Use of medication that may interfere with the effects of the study medication.Patients must be willing to discontinue medications in cases where drug-relatedinteractions are possible (the washout phase will be at least 5 times the particulardrug's half-life [typically 3-7 days] prior to the respective study session).Discontinuation of medication must be judged to be acceptable by the responsibleinvestigator.

• Women are excluded from substance intervention during pregnancy or breastfeeding.

• nParticipation in another clinical trial (currently or within the last 30 days)